36 reports

In addition, the development of drugs for genetic obesity is one of the key trends in the market and will likely impact the market growth.

  • Depression
  • Allergan plc
  • Eli Lilly & Co.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

This may be related to genetic predisposition, chronic stress, or illness, certain medications etc.

  • Depression
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • 1.2 TYPES
  • TYPES OF DEPRESSION

There are traces showing that depression runs in families, suggesting a genetic link.

  • Depression
  • World
  • AstraZeneca PLC
  • Lundbeck Inc.
  • Pfizer Inc.
  • MHDS - MARKET SIZE AND FORECAST 2017-2022

AD is one of the most common types of NDDs.

  • Depression
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • 3.1 ETIOLOGY AND PATHOPHYSIOLOGY
  • 4.1 DISEASE BACKGROUND

Saying a patient with this profile or genetic makeup, he will benefit from a drug type A, B, or C.

  • Depression
  • Alkermes plc
  • Allergan plc
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Executive Summary
  • 7MM, 12-MONTH TOTAL PREVALENT CASES OF MDD,

Psychiatry; ##(##): ##-##.

  • Depression
  • Japan
  • United States
  • World
  • Forecast
  • Changes in lifestyle
  • 07. Disorder Overview

Major depressive disorder is mostly caused by psychological, biological, genetic, and social factors.

  • Depression
  • Actavis plc
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • 07.1 TYPES OF DEPRESSION
  • 11. Market Growth Drivers

Major depressive disorder is mostly caused by psychological, biological, genetic, and social factors.

  • Depression
  • United States
  • Actavis plc
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • GENESIGHT TEST - MDD - PRODUCT DESCRIPTION
  • BIPOLAR DISORDER MAJOR DEPRESSIVE DISORDER

Summary Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases.The company’s product portfolio includes molecular diagnostic testing products that analyze genes, their expression levels...

  • Autoimmune Disease
  • Depression
  • Targeted Therapy
  • United States
  • Myriad Genetics, Inc.

To raise this finance, the company issued equity securities for one investor.

  • Depression
  • Pharmaceutical
  • United States
  • Company
  • RespireRx Pharmaceuticals Inc.

Study ##B - Patients with severe PPD (n=##): Patients were randomized to one of three treatment groups (brexanolone ## g/ kg/ hour, brexanolone ## g/ kg/ hour, or placebo) on a ##:##:## basis.

  • Depression
  • Therapy
  • United States
  • Company Operations
  • SAGE Therapeutics
  • Global Markets Direct Report Coverage

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ## and ## respectively.

  • Depression
  • Therapy
  • United States
  • World
  • Product Initiative

Angelman Syndrome (AS) is a rare congenital genetic disorder caused by a lack of function in the UBE##A gene on the maternal ##th chromosome.

  • Depression
  • United States
  • Company
  • Company Operations
  • Neuralstem, Inc.
  • SMALL MOLECULE TO TARGET SLC6A15 FOR PSYCHATRIC STRESS DISORDERS - DRUG PROFILE
  • R&D Progress

Decreased SLC##A## expression, due to genetic or environmental factors, might alter neuronal circuits related to the susceptibility of disease.

  • Depression
  • United States
  • Company
  • Product Initiative
  • Anavex Life Sciences Corp.
  • Global Markets Direct Report Coverage

The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are ##, ##, ## and ## respectively.

  • Depression
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Depression
  • Therapy
  • World
  • Product Initiative
  • RespireRx Pharmaceuticals Inc.

Celsis will also determine genetic variations in VistaGen' s pluripotent stem cell lines that are important to drug development.

  • Depression
  • Therapy
  • United States
  • Litigation And Patent
  • VistaGen Therapeutics, Inc.

There was one serious adverse event (confusion) reported in one of the two patients who received oral solution.

  • Depression
  • Therapy
  • United States
  • Company Financials
  • SAGE Therapeutics
  • Introduction

This includes data from multiple genetically modified rodent models where reduction in NR##B expression impairs cognitive performance and increases in NR##B expression improve cognitive performance.

  • Depression
  • Therapy
  • United States
  • Product Initiative
  • NeurOp, Inc.

More recently, the group found a genetic basis for those eye movements.

  • Depression
  • Healthcare
  • United States
  • Deals & Alliance
  • GlobalData's company

Celsis will also determine genetic variations in VistaGen' s pluripotent stem cell lines that are important to drug development.

  • Depression
  • Healthcare
  • Therapy
  • United States
  • VistaGen Therapeutics, Inc.

The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, Discovery and Unknown stages are ##, ##, ##, ##, ## and ## respectively.

  • Depression
  • Pathology
  • Therapy
  • United States
  • Product Initiative

University of Utah undertakes research on animal subjects, radiation and laboratory safety, resource for genetic and epidemiologic research, and others.

  • Clinical Trial
  • Depression
  • Mental Health
  • Therapy
  • GlobalData's company
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Depression
  • Therapy
  • World
  • Product Initiative
  • 1.2 CAUSES OF MDD

There are traces showing that depression runs in families, suggesting a genetic link.

  • Depression
  • Therapy
  • United States
  • Market Size
  • Eli Lilly & Co.
  • DEPRESSION - PIPELINE BY BOEHRINGER INGELHEIM GMBH
  • ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) - PIPELINE BY P2D BIOSCIENCE

Oct ##, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder Medgenics, Inc.

  • Depression
  • Psychotic Disorder
  • United States
  • Company
  • Product Initiative
  • SAGE-217 - DRUG PROFILE

It was also under development as an intravenous therapy for refractory status epilepticus (RSE) and as an oral therapy for orphan genetic epilepsy disorders, such as Dravet syndrome, Rett syndrome and Fragile X syndromes.

  • Depression
  • Sleep Aid
  • United States
  • World
  • Product Initiative
  • SMALL MOLECULE TO INHIBIT SLC6A15 FOR PSYCHATRIC STRESS DISORDERS - DRUG PROFILE
  • NSI-189 - DRUG PROFILE

The studies primary endpoints will be the number of malignant cells, of the respective cancers, genetically sensitive to PP##A inhibition.

  • Depression
  • United States
  • Company
  • Product Initiative
  • Anavex Life Sciences Corp.
  • SMALL MOLECULE TO TARGET SLC6A15 FOR MAJOR DEPRESSIVE DISORDER AND ANXIETY DISORDERS - DRUG PROFILE
  • MIR-135 - DRUG PROFILE

The Company also reported that, in a genetic model of type ## diabetes (db/ db mouse), NSI-## treatment showed significant reversal in all of the same indices of neuropathy.

  • Depression
  • United States
  • Company
  • Product Initiative
  • Allergan plc

In this trial, over ## patients will be randomized to receive one of four treatments ## mg ITI-##, ## mg ITI-##, ## mg risperidone (active control) or placebo in a ##:##:##:## ratio.

  • Bipolar Disorder
  • Depression
  • United States
  • Product Initiative
  • Intra-Cellular Therapies, Inc.